이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

SynAct Pharma 대차 대조표 상태

재무 상태 기준 확인 4/6

SynAct Pharma 의 총 주주 지분은 SEK152.3M 이고 총 부채는 SEK0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 SEK213.4M 및 SEK61.1M 입니다.

주요 정보

부채 비율

SEK 0

부채

이자 보상 비율	n/a
현금	SEK 62.80m
주식	SEK 186.99m
총 부채	SEK 54.06m
총 자산	SEK 241.05m

최근 재무 상태 업데이트

Here's Why We're Not Too Worried About SynAct Pharma's (NGM:SYNACT) Cash Burn Situation

Sep 03

SynAct Pharma (NGM:SYNACT) Is In A Good Position To Deliver On Growth Plans

Apr 07

Companies Like SynAct Pharma (NGM:SYNACT) Are In A Position To Invest In Growth

Dec 23

Recent updates

We Think SynAct Pharma (STO:SYNACT) Needs To Drive Business Growth Carefully

Sep 18

Here's Why We're Watching SynAct Pharma's (STO:SYNACT) Cash Burn Situation

Sep 04

Is SynAct Pharma (NGM:SYNACT) In A Good Position To Deliver On Growth Plans?

Jan 18

Here's Why We're Not Too Worried About SynAct Pharma's (NGM:SYNACT) Cash Burn Situation

Sep 03

SynAct Pharma (NGM:SYNACT) Is In A Good Position To Deliver On Growth Plans

Apr 07

Companies Like SynAct Pharma (NGM:SYNACT) Are In A Position To Invest In Growth

Dec 23

재무 상태 분석

단기부채: SYNACT 의 단기 자산 ( SEK62.8M )이 단기 부채( SEK27.2M ).

장기 부채: SYNACT 의 단기 자산( SEK62.8M )이 장기 부채( SEK33.9M ).

부채 대 자본 내역 및 분석

부채 수준: SYNACT 부채가 없습니다.

부채 감소: SYNACT 지난 5년간 부채가 없습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: SYNACT 현재 무료 현금 흐름을 기준으로 1년 미만의 cash runway를 보유하고 있습니다.

예측 현금 활주로: 무료 현금 흐름이 매년 32 %의 역사적 비율로 계속 감소할 경우 SYNACT 의 현금 활주로는 1년 미만입니다.

SynAct Pharma 대차 대조표 상태

재무 상태 기준 확인 4/6

주요 정보

최근 재무 상태 업데이트

We Think SynAct Pharma (STO:SYNACT) Needs To Drive Business Growth Carefully

Here's Why We're Watching SynAct Pharma's (STO:SYNACT) Cash Burn Situation

Is SynAct Pharma (NGM:SYNACT) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About SynAct Pharma's (NGM:SYNACT) Cash Burn Situation

SynAct Pharma (NGM:SYNACT) Is In A Good Position To Deliver On Growth Plans

Companies Like SynAct Pharma (NGM:SYNACT) Are In A Position To Invest In Growth

Recent updates

SynAct Pharma AB Initiates the Phase 2b Advance Study with Resomelagon (AP1189) in the US

We Think SynAct Pharma (STO:SYNACT) Needs To Drive Business Growth Carefully

New minor risk - Share price stability

SynAct Pharma AB Initiates Filing Process for Phase 2b Advance Study with Resomelagon

Chief Operating Officer recently bought kr1.9m worth of stock

SynAct Pharma AB has completed a Follow-on Equity Offering in the amount of SEK 49.239162 million.

New major risk - Revenue and earnings growth

Chief Operating Officer recently sold kr145k worth of stock

SynAct Pharma AB has filed a Follow-on Equity Offering in the amount of SEK 45 million.

SynAct Pharma AB Announces CEO Changes

SynAct Pharma AB Announces Outcomes of the Independent Audit of the 4-Week Resolve P2a Clinical Trial in Rheumatoid Arthritis

SynAct Pharma AB (publ) Announces Resignation of Marina Bozilenko as Member of the Board of Directors

New major risk - Financial position

SynAct Pharma AB to Report Q3, 2024 Results on Oct 30, 2024

SynAct Pharma Announces Additional Data from the Expand P2b Clinical Trial Supporting Continued Development of the Compound in Rheumatoid Arthritis

SynAct Pharma AB to Report Q4, 2023 Results on Feb 23, 2024

High number of new and inexperienced directors

Synact Pharma Appoints Kristen Harting as Chief Medical Officer, Effective 15 February 2024

Synact Pharma Expands Its Rheumatology Clinical Advisory Board with Three New Highly Experienced Advisors

SynAct Pharma AB, Annual General Meeting, May 23, 2024

SynAct Pharma AB has completed a Follow-on Equity Offering in the amount of SEK 60.525 million.

SynAct Pharma AB Announces Evaluation of the 4-Week RESOLVE P2a Clinical Trial in Moderate to Severe Active Rheumatoid Arthritis Patients with an incomplete Response to Methotrexate

SynAct Pharma AB Announces Additional Data from the Expands P2b Clinical Trial Further Supporting Efficacy and Activity seen in Patients with Elevated CRP

SynAct Pharma AB Announces Additional Data from the EXPAND P2b Clinical Trial and Identifies Population with Responsiveness to Resomelagon

Synact Pharma Announces Top Line Data from the 12-Week Expand P2b Clinical Trial in Severe Active Newly Diagnosed Rheumatoid Arthritis Patients

SynAct Pharma AB (Publ) Completes Dosing in Part A of Combined Phase 2A/B Resomelagon (AP1189) in Rheumatoid Arthritis (RA)

SynAct Pharma AB (publ) Completes Patient Recruitment for Part A of Combined Phase 2a/b RESOLVE Study of Resomelagon (AP1189) in Rheumatoid Arthritis

SynAct Pharma AB (publ) Announces the Completion of Dosing in the Phase 2b Expand Study of Resomelagon (AP1189) in Early Severe Rheumatoid Arthritis Patients

Chief Operating Officer recently bought kr78k worth of stock

SynAct Pharma AB Announces Appointment of Thomas Von Koch as Board Member

SynAct Pharma AB Appoints Björn Westberg as Chief Financial Officer

SynAct Pharma AB to Report Q1, 2023 Results on May 05, 2023

SynAct Pharma AB (OM:SYNACT) completed the acquisition of TXP Pharma AG from Boesen Biotech ApS, GL Capital AB, TJ Biotech Holding ApS, Quantass ApS, and James Knight.

SynAct Pharma AB Announces Change in Nomination Committee Prior to Agm 2023

Chief Operating Officer recently sold kr3.4m worth of stock

SynAct Pharma AB (OM:SYNACT) entered into a conditional agreement to acquire TXP Pharma AG from Boesen Biotech Aps, Glcapital Ab, TJ Biotech Holding ApS, Quantass ApS, and James Knight for approximately SEK 190 million.

No independent directors

SynAct Pharma AB Receives IND Clearance from the FDA for Phase 2A/B Trial of Ap1189 in Ra

SynAct Pharma AB, Annual General Meeting, May 25, 2023

Synact Submits Ind and Recruits First Patient

Synact Pharma Submits IND for US Phase 2A/B Clinical Trial

SynAct Pharma AB (Publ) Enrolls First Patient in Phase 2b Trial of Ap1189 in RA

SynAct Pharma AB Announces Approval of Amended Study Protocol for the Phase 2A Study in iMN

Here's Why We're Watching SynAct Pharma's (STO:SYNACT) Cash Burn Situation

SynAct Pharma AB (publ) Announces That the Clinical Trial Application to Initiate the Clinical Phase 2B Study, Expand

SynAct Pharma AB Improves the Design of the Ongoing Phase 2A Study in Imn

SynAct Pharma AB Improves the Design of the Ongoing Phase 2A Study in Imn

Synact Pharma Receives pre-IND Response from the U.S. Food and Drug Administration

SynAct Pharma Submits CTA for Clinical Phase 2b Study in RA

John Haurum Declines Re-Election as Board Member of SynAct Pharma AB

SynAct Pharma AB Completes Clinical Pharmacokinetic Test of Ap1189 Tablet

No independent directors

Is SynAct Pharma (NGM:SYNACT) In A Good Position To Deliver On Growth Plans?

SynAct Pharma AB Announces Additional Data from the BEGIN Study

SynAct Pharma AB Reports Positive PK Data on AP1189 Tablets

SynAct Pharma AB Completes Patient Recruitment to the Phase 2A Begin Study of Ap1189 in Early Severe Rheumatoid Arthritis

Here's Why We're Not Too Worried About SynAct Pharma's (NGM:SYNACT) Cash Burn Situation

SynAct Pharma AB Provides an Update on Patient Recruitment in the Phase 2a Clinical Trial of AP1189 in Rheumatoid Arthritis

SynAct Pharma AB Announces Grant of Key European Patent Covering Ap1189

Chief Medical Officer Thierry Duvauchelle has left the company

Synact Pharma AB Announces Positive Data from A Phase 2A Trial of Ap1189 in Covid-19 Infected Patients

SynAct Pharma Files Patent Applications Related to AP1189 Derived APIs and Oral Formulations

SynAct Pharma Updates Phase II study with AP1189

Synact Pharma Expands Ap1189 Begin Study in Rheumatoid Arthritis Uk Version

SynAct Pharma (NGM:SYNACT) Is In A Good Position To Deliver On Growth Plans

SynAct Pharma AB Initiates Dosing in Part 2 of the Clinical Phase II Study with AP1189 in Covid-19 Infected Patients UK Version

Chief Financial Officer recently sold kr2.9m worth of stock

SynAct Pharma AB Names James Knight as Chief Business Officer

New 90-day high: kr61.00